EHA 2019 – turnaround puts Arqule in the takeover frame
A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
Imbruvica resistance provides early but fertile development ground
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
